New drug combo aims to boost cancer treatment
NCT ID NCT02379416
First seen Mar 06, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed to find the best dose and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nilotinib and paclitaxel
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early phase 1 trial with only 47 participants, focused on safety and dosing. The combination may not shrink tumors or may cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.